A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
But sasanlimab's use looks set to remain narrow.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
